Amarin Corporation's (AMRN) FDA Review is on Track, 2020 Should See Acceleration - Citi
Tweet Send to a Friend
Citi analyst Joel Beatty reiterated a Buy rating and $23.00 price target on Amarin Corporation (NASDAQ: AMRN) noting that for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
